1. Home
  2. LTRX vs TLSI Comparison

LTRX vs TLSI Comparison

Compare LTRX & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantronix Inc.

LTRX

Lantronix Inc.

HOLD

Current Price

$6.05

Market Cap

237.4M

ML Signal

HOLD

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$5.40

Market Cap

272.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTRX
TLSI
Founded
1989
2010
Country
United States
United States
Employees
N/A
110
Industry
Computer Communications Equipment
Medical Specialities
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
237.4M
272.3M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
LTRX
TLSI
Price
$6.05
$5.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$6.50
$12.00
AVG Volume (30 Days)
1.4M
144.7K
Earning Date
05-05-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$122,923,000.00
N/A
Revenue This Year
$1.12
$55.47
Revenue Next Year
$15.27
$40.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.91
$3.42
52 Week High
$8.24
$7.95

Technical Indicators

Market Signals
Indicator
LTRX
TLSI
Relative Strength Index (RSI) 50.49 51.92
Support Level $6.05 $4.90
Resistance Level $6.75 $5.61
Average True Range (ATR) 0.44 0.33
MACD -0.00 0.11
Stochastic Oscillator 61.23 73.95

Price Performance

Historical Comparison
LTRX
TLSI

About LTRX Lantronix Inc.

Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

Share on Social Networks: